ଟେପୋଟିନିବ

ଟେପୋଟିନିବ
Clinical data
Trade names	Tepmetko
Synonyms	EMD-1214063
AHFS/Drugs.com	monograph
data	US DailyMed: Tepotinib;
Pregnancy; category	AU: D ; Not recommended;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ; Rx-only;
Identifiers
	IUPAC name 3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin3-yl}benzonitrile;
Chemical and physical data
Formula	C29H28N6O2
Molar mass	୪୯୨.୫୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1;
	InChI InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3; Key:AHYMHWXQRWRBKT-UHFFFAOYSA-N;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Tepotinib

ଟେପୋଟିନିବ, ବେପାର ନାମ ଟେପମେଟକୋ, ବିକ୍ରି ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଣ-ଛୋଟ ଜୀବକୋଷ ଫୁସଫୁସ କର୍କଟ (NSCLC) ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ମେଟାଷ୍ଟାଟିକ୍ ରୋଗରେ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁଥିରେ ମେସେନ‌କାଇମାଲ-ଏପିଥେଲିଆଲ ଟ୍ରାଞ୍ଜିସନ ଏକସନ (ଏମଇଟି/ MET) ସ୍କିପିଙ୍ଗ୍ ଥାଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁଲା, ଥକାପଣ, ଅଇ, ତରଳ ଝାଡ଼ା, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, କମ୍ ରକ୍ତ ସୋଡିୟମ୍ ଏବଂ ଅଣନିଶ୍ୱାସ ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନାଇଟିସ୍ ଏବଂ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ଯାହା ଏମଇଟିକୁ ଅବରୋଧ କରେ । ^[୪] ^[୭]

୨୦୨୦ରେ ଜାପାନରେ, ୨୦୨୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଓ ୨୦୨୨ରେ ୟୁରୋପରେ ଟେପୋଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪]^[୮]^[୯] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୨ ମସିହାରେ ଏହାର ଏକ ମାସର ଖର୍ଚ୍ଚ ପ୍ରାୟ ୭୨୦୦ ପାଉଣ୍ଡ ଥିଲା । ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ୨୨୮୦୦ ଡଲାର ଅଟେ।^[୧୦]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Tepmetko APMDS". Therapeutic Goods Administration (TGA). 27 January 2022. Retrieved 5 February 2022.{{cite web}}: CS1 maint: url-status (link)
↑ "Summary Basis of Decision (SBD) for Tepmetko". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
↑ "Tepmetko EPAR". European Medicines Agency (EMA). 14 December 2021. Archived from the original on 5 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Tepmetko- tepotinib hydrochloride tablet". DailyMed. Archived from the original on 27 November 2021. Retrieved 13 February 2021.
↑ "FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer". Food and Drug Administration. 3 February 2021. Archived from the original on 3 February 2021. Retrieved 3 February 2021. This article incorporates text from this source, which is in the public domain.
↑ "FDA Approves Tepmetko as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations". EMD Serono (Press release). 3 February 2021. Archived from the original on 4 February 2021. Retrieved 3 February 2021.
↑ "Tepmetko". EMA. Archived from the original on 5 May 2022. Retrieved 31 October 2022.
↑ "Tepmetko (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations" (Press release). Merck KGaA. 25 March 2020. Retrieved 3 February 2021.
↑ "Tepotinib". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 21 January 2022. Retrieved 31 October 2022.
↑ "Tepmetko". Archived from the original on 31 October 2022. Retrieved 31 October 2022.

[Tepmetko_APMDS-1] ୧.୦ ^୧.୧ "Tepmetko APMDS". Therapeutic Goods Administration (TGA). 27 January 2022. Retrieved 5 February 2022.{{cite web}}: CS1 maint: url-status (link)

[2] "Summary Basis of Decision (SBD) for Tepmetko". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

[-"Tepmetko-3] "Tepmetko EPAR". European Medicines Agency (EMA). 14 December 2021. Archived from the original on 5 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Tepmetko- tepotinib hydrochloride tablet". DailyMed. Archived from the original on 27 November 2021. Retrieved 13 February 2021.

[FDA_Tepmetko-5] "FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer". Food and Drug Administration. 3 February 2021. Archived from the original on 3 February 2021. Retrieved 3 February 2021. This article incorporates text from this source, which is in the public domain.

[EMD_PR-6] "FDA Approves Tepmetko as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations". EMD Serono (Press release). 3 February 2021. Archived from the original on 4 February 2021. Retrieved 3 February 2021.

[EPAR2022-7] "Tepmetko". EMA. Archived from the original on 5 May 2022. Retrieved 31 October 2022.

[Japan2020-8] "Tepmetko (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations" (Press release). Merck KGaA. 25 March 2020. Retrieved 3 February 2021.

[SPS2022-9] "Tepotinib". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 21 January 2022. Retrieved 31 October 2022.

[10] "Tepmetko". Archived from the original on 31 October 2022. Retrieved 31 October 2022.

[୧]

[୨]

[୪]

[୫]

[୩]

[୬]

[୭]

[୮]

[୯]

[୧୦]